Eli Lilly and Company has become a key player in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve https://amiewspo200576.blogsumer.com/36675698/eli-lilly-s